Briacell Therap (BCTX) Competitors

$4.05 -0.13 (-3.11%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$4.08 +0.04 (+0.86%)

As of 04:44 AM Eastern

BCTX vs. PEPG, AIFC, TTRX, CRDF, and BMEA

Should you buy Briacell Therap stock or one of its competitors? MarketBeat compares Briacell Therap with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Briacell Therap include PepGen (PEPG), ALT5 Sigma (AIFC), Turn Therapeutics (TTRX), Cardiff Oncology (CRDF), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry.

How does Briacell Therap compare to PepGen?

PepGen (NASDAQ:PEPG) and Briacell Therap (NASDAQ:BCTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

PepGen presently has a consensus target price of $11.60, indicating a potential upside of 603.03%. Given PepGen's stronger consensus rating and higher possible upside, research analysts plainly believe PepGen is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PepGen is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$2.41	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A

PepGen's return on equity of -59.89% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
Briacell Therap	N/A	-173.08%	-139.64%

PepGen has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

58.0% of PepGen shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 1.3% of PepGen shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Briacell Therap had 3 more articles in the media than PepGen. MarketBeat recorded 6 mentions for Briacell Therap and 3 mentions for PepGen. PepGen's average media sentiment score of 1.03 beat Briacell Therap's score of -0.37 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

PepGen beats Briacell Therap on 10 of the 13 factors compared between the two stocks.

How does Briacell Therap compare to ALT5 Sigma?

Briacell Therap (NASDAQ:BCTX) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Briacell Therap has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
ALT5 Sigma	$24.84M	5.27	-$344.51M	N/A	N/A

Briacell Therap has a net margin of 0.00% compared to ALT5 Sigma's net margin of -1,386.90%. ALT5 Sigma's return on equity of -50.52% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
ALT5 Sigma	-1,386.90%	-50.52%	-45.05%

Briacell Therap has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.69, indicating that its share price is 69% more volatile than the broader market.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Comparatively, 0.2% of ALT5 Sigma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Briacell Therap had 3 more articles in the media than ALT5 Sigma. MarketBeat recorded 6 mentions for Briacell Therap and 3 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 1.08 beat Briacell Therap's score of -0.37 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
ALT5 Sigma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Briacell Therap and ALT5 Sigma tied by winning 5 of the 10 factors compared between the two stocks.

How does Briacell Therap compare to Turn Therapeutics?

Briacell Therap (NASDAQ:BCTX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

15.4% of Briacell Therap shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Turn Therapeutics has a consensus target price of $8.00, indicating a potential upside of 99.00%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Turn Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.16	N/A

Turn Therapeutics' return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Turn Therapeutics	N/A	N/A	N/A

In the previous week, Briacell Therap had 3 more articles in the media than Turn Therapeutics. MarketBeat recorded 6 mentions for Briacell Therap and 3 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 1.47 beat Briacell Therap's score of -0.37 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Turn Therapeutics beats Briacell Therap on 8 of the 12 factors compared between the two stocks.

How does Briacell Therap compare to Cardiff Oncology?

Briacell Therap (NASDAQ:BCTX) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cardiff Oncology has a consensus target price of $10.10, suggesting a potential upside of 483.82%. Given Cardiff Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Cardiff Oncology is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Briacell Therap has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
Cardiff Oncology	$590K	200.47	-$45.85M	-$0.69	N/A

Briacell Therap has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market.

Briacell Therap has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,733.22%. Cardiff Oncology's return on equity of -82.01% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%

In the previous week, Briacell Therap had 3 more articles in the media than Cardiff Oncology. MarketBeat recorded 6 mentions for Briacell Therap and 3 mentions for Cardiff Oncology. Cardiff Oncology's average media sentiment score of 0.94 beat Briacell Therap's score of -0.37 indicating that Cardiff Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cardiff Oncology beats Briacell Therap on 11 of the 15 factors compared between the two stocks.

How does Briacell Therap compare to Biomea Fusion?

Briacell Therap (NASDAQ:BCTX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Briacell Therap's return on equity of -173.08% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
Biomea Fusion	N/A	-265.37%	-103.96%

Biomea Fusion is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$0.68	N/A

Biomea Fusion has a consensus target price of $8.29, suggesting a potential upside of 479.42%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

15.4% of Briacell Therap shares are owned by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are owned by institutional investors. 0.7% of Briacell Therap shares are owned by company insiders. Comparatively, 18.4% of Biomea Fusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Biomea Fusion had 4 more articles in the media than Briacell Therap. MarketBeat recorded 10 mentions for Biomea Fusion and 6 mentions for Briacell Therap. Biomea Fusion's average media sentiment score of 0.98 beat Briacell Therap's score of -0.37 indicating that Biomea Fusion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Biomea Fusion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Briacell Therap has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.32, indicating that its stock price is 132% less volatile than the broader market.

Summary

Biomea Fusion beats Briacell Therap on 10 of the 14 factors compared between the two stocks.

Get Briacell Therap News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCTX vs. The Competition

Export

Metric	Briacell Therap	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.31M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.17	18.47	20.66	25.63
Price / Sales	N/A	294.84	545.69	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	0.44	6.93	9.94	6.97
Net Income	-$26.31M	$24.11M	$3.55B	$333.62M
7 Day Performance	-3.34%	5.89%	1.69%	1.09%
1 Month Performance	-12.34%	-0.91%	0.48%	3.08%
1 Year Performance	-86.13%	74.58%	39.38%	35.68%

Briacell Therap Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCTX Briacell Therap	0.2409 of 5 stars	$4.05 -3.1%	N/A	-86.5%	$30.31M	N/A	N/A	8	Short Interest Increase
PEPG PepGen	3.8436 of 5 stars	$1.71 +1.5%	$11.60 +580.4%	+19.6%	$117.86M	N/A	N/A	30	Positive News Earnings Report Analyst Forecast
AIFC ALT5 Sigma	0.301 of 5 stars	$0.91 +1.6%	N/A	-83.3%	$116.27M	$24.84M	N/A	170	Positive News
TTRX Turn Therapeutics	3.3686 of 5 stars	$3.89 -2.3%	$8.00 +105.7%	N/A	$115.88M	N/A	N/A	2	News Coverage Positive News Earnings Report Gap Down
CRDF Cardiff Oncology	1.7226 of 5 stars	$1.67 +1.5%	$10.10 +506.6%	-35.2%	$113.84M	$590K	N/A	20	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCTX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Briacell Therap (BCTX) Competitors

BCTX vs. PEPG, AIFC, TTRX, CRDF, and BMEA

How does Briacell Therap compare to PepGen?

Summary

How does Briacell Therap compare to ALT5 Sigma?

Summary

How does Briacell Therap compare to Turn Therapeutics?

Summary

How does Briacell Therap compare to Cardiff Oncology?

Summary

How does Briacell Therap compare to Biomea Fusion?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Briacell Therap (BCTX) Competitors

BCTX vs. PEPG, AIFC, TTRX, CRDF, and BMEA

How does Briacell Therap compare to PepGen?

Do analysts recommend PEPG or BCTX?

Which has stronger valuation & earnings, PEPG or BCTX?

Is PEPG or BCTX more profitable?

Which has more risk and volatility, PEPG or BCTX?

Do insiders and institutionals believe in PEPG or BCTX?

Does the media refer more to PEPG or BCTX?

Summary

How does Briacell Therap compare to ALT5 Sigma?

Do analysts rate BCTX or AIFC?

Which has preferable earnings and valuation, BCTX or AIFC?

Is BCTX or AIFC more profitable?

Which has more volatility and risk, BCTX or AIFC?

Do institutionals and insiders believe in BCTX or AIFC?

Does the media prefer BCTX or AIFC?

Summary

How does Briacell Therap compare to Turn Therapeutics?

Do institutionals and insiders believe in BCTX or TTRX?

Do analysts rate BCTX or TTRX?

Which has preferable earnings and valuation, BCTX or TTRX?

Is BCTX or TTRX more profitable?

Does the media prefer BCTX or TTRX?

Summary

How does Briacell Therap compare to Cardiff Oncology?

Do insiders & institutionals believe in BCTX or CRDF?

Do analysts recommend BCTX or CRDF?

Which has higher earnings & valuation, BCTX or CRDF?

Which has more risk and volatility, BCTX or CRDF?

Is BCTX or CRDF more profitable?

Does the media favor BCTX or CRDF?

Summary

How does Briacell Therap compare to Biomea Fusion?

Is BCTX or BMEA more profitable?

Which has higher earnings & valuation, BCTX or BMEA?

Do analysts recommend BCTX or BMEA?

Do insiders & institutionals believe in BCTX or BMEA?

Does the media favor BCTX or BMEA?

Which has more risk and volatility, BCTX or BMEA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCTX vs. The Competition

Briacell Therap Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools